CN108699148A - 配制用于向人施用的抗cd28人源化抗体 - Google Patents
配制用于向人施用的抗cd28人源化抗体 Download PDFInfo
- Publication number
- CN108699148A CN108699148A CN201680080258.4A CN201680080258A CN108699148A CN 108699148 A CN108699148 A CN 108699148A CN 201680080258 A CN201680080258 A CN 201680080258A CN 108699148 A CN108699148 A CN 108699148A
- Authority
- CN
- China
- Prior art keywords
- weeks
- fab
- once
- optional
- antibody fragments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Wood Science & Technology (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15200281.2 | 2015-12-15 | ||
| EP15200281 | 2015-12-15 | ||
| EP16306537 | 2016-11-22 | ||
| EP16306537.8 | 2016-11-22 | ||
| PCT/EP2016/081286 WO2017103003A1 (en) | 2015-12-15 | 2016-12-15 | Anti-cd28 humanized antibodies formulated for administration to humans |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108699148A true CN108699148A (zh) | 2018-10-23 |
Family
ID=57737702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680080258.4A Pending CN108699148A (zh) | 2015-12-15 | 2016-12-15 | 配制用于向人施用的抗cd28人源化抗体 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US20180215824A1 (enExample) |
| EP (2) | EP3390450B1 (enExample) |
| JP (1) | JP6923528B2 (enExample) |
| KR (2) | KR20180087428A (enExample) |
| CN (1) | CN108699148A (enExample) |
| CY (1) | CY1124141T1 (enExample) |
| DK (1) | DK3390450T3 (enExample) |
| ES (1) | ES2862395T3 (enExample) |
| HR (1) | HRP20210445T1 (enExample) |
| HU (1) | HUE053736T2 (enExample) |
| LT (1) | LT3390450T (enExample) |
| PL (1) | PL3390450T3 (enExample) |
| RS (1) | RS61958B1 (enExample) |
| SI (1) | SI3390450T1 (enExample) |
| SM (1) | SMT202100185T1 (enExample) |
| WO (1) | WO2017103003A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011101791A1 (en) * | 2010-02-18 | 2011-08-25 | Tcl Pharma | Anti-cd28 humanized antibodies |
| KR102607909B1 (ko) | 2020-08-19 | 2023-12-01 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
| EP4380604A1 (en) | 2021-08-05 | 2024-06-12 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
| JP2024534910A (ja) | 2021-09-03 | 2024-09-26 | ジーオー セラピューティクス,インコーポレイテッド | 抗グリコlamp1抗体およびその使用 |
| CA3230934A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
| CN119110809A (zh) | 2022-02-23 | 2024-12-10 | Xencor股份有限公司 | 抗CD28 x抗PSMA抗体 |
| EP4482865A1 (en) * | 2022-02-24 | 2025-01-01 | Xencor, Inc. | Anti-cd28 x anti-trop2 antibodies |
| AU2023356326A1 (en) | 2022-10-06 | 2025-03-27 | Bicara Therapeutics Inc. | Multispecific proteins and related methods |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1563092A (zh) * | 2004-04-01 | 2005-01-12 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28单链三特异抗体 |
| US20060003927A1 (en) * | 2002-10-09 | 2006-01-05 | Champion Brian R | Modulation of immune function |
| CN1981031A (zh) * | 2004-03-05 | 2007-06-13 | 宾久法尼亚大学理事会 | 调节性t细胞及它们在免疫治疗和抑制自身免疫反应中的应用 |
| WO2011101791A1 (en) * | 2010-02-18 | 2011-08-25 | Tcl Pharma | Anti-cd28 humanized antibodies |
| US20130230540A1 (en) * | 2008-07-18 | 2013-09-05 | Domantis Limited | Compositions monovalent for cd28 binding and methods of use |
| CN103596593A (zh) * | 2011-03-11 | 2014-02-19 | 贝丝以色列女执事医疗中心 | 抗cd40抗体及其用途 |
| CN105073110A (zh) * | 2013-03-25 | 2015-11-18 | 株式会社Lg生命科学 | 通过诱导分化成调节性t细胞和促进调节性t细胞增殖来抑制免疫应答的药物组合物 |
-
2016
- 2016-12-15 HR HRP20210445TT patent/HRP20210445T1/hr unknown
- 2016-12-15 EP EP16822423.6A patent/EP3390450B1/en active Active
- 2016-12-15 WO PCT/EP2016/081286 patent/WO2017103003A1/en not_active Ceased
- 2016-12-15 KR KR1020187020218A patent/KR20180087428A/ko not_active Ceased
- 2016-12-15 LT LTEP16822423.6T patent/LT3390450T/lt unknown
- 2016-12-15 PL PL16822423T patent/PL3390450T3/pl unknown
- 2016-12-15 HU HUE16822423A patent/HUE053736T2/hu unknown
- 2016-12-15 EP EP21150940.1A patent/EP3868785A1/en active Pending
- 2016-12-15 ES ES16822423T patent/ES2862395T3/es active Active
- 2016-12-15 CN CN201680080258.4A patent/CN108699148A/zh active Pending
- 2016-12-15 SI SI201631115T patent/SI3390450T1/sl unknown
- 2016-12-15 RS RS20210451A patent/RS61958B1/sr unknown
- 2016-12-15 KR KR1020247030946A patent/KR20240144440A/ko active Pending
- 2016-12-15 SM SM20210185T patent/SMT202100185T1/it unknown
- 2016-12-15 JP JP2018532040A patent/JP6923528B2/ja active Active
- 2016-12-15 DK DK16822423.6T patent/DK3390450T3/da active
-
2018
- 2018-03-12 US US15/918,699 patent/US20180215824A1/en not_active Abandoned
-
2019
- 2019-10-24 US US16/662,399 patent/US20200115453A1/en not_active Abandoned
-
2021
- 2021-04-16 CY CY20211100337T patent/CY1124141T1/el unknown
-
2022
- 2022-02-10 US US17/668,969 patent/US20220411510A1/en not_active Abandoned
-
2023
- 2023-09-08 US US18/463,454 patent/US20250051446A1/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060003927A1 (en) * | 2002-10-09 | 2006-01-05 | Champion Brian R | Modulation of immune function |
| CN1981031A (zh) * | 2004-03-05 | 2007-06-13 | 宾久法尼亚大学理事会 | 调节性t细胞及它们在免疫治疗和抑制自身免疫反应中的应用 |
| CN1563092A (zh) * | 2004-04-01 | 2005-01-12 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28单链三特异抗体 |
| US20130230540A1 (en) * | 2008-07-18 | 2013-09-05 | Domantis Limited | Compositions monovalent for cd28 binding and methods of use |
| WO2011101791A1 (en) * | 2010-02-18 | 2011-08-25 | Tcl Pharma | Anti-cd28 humanized antibodies |
| CN103596593A (zh) * | 2011-03-11 | 2014-02-19 | 贝丝以色列女执事医疗中心 | 抗cd40抗体及其用途 |
| CN105073110A (zh) * | 2013-03-25 | 2015-11-18 | 株式会社Lg生命科学 | 通过诱导分化成调节性t细胞和促进调节性t细胞增殖来抑制免疫应答的药物组合物 |
Non-Patent Citations (8)
| Title |
|---|
| L G LUM等: "Coactivation with anti-CD28 monoclonal antibody enhances anti-CD3 monoclonal antibody-induced proliferation and IL-2 synthesis in T cells from autologous bone marrow transplant recipients", 《BONE MARROW TRANSPLANT》 * |
| L.H.BOOKBINDER等: "A recombinant human enzyme for enhanced interstitial transport of therapeutics", 《JOURNAL OF CONTROLLED RELEASE》 * |
| N POIRIER等: "FR104, an antagonist anti-CD28 monovalent fab" antibody, prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate renal allograft", 《AM J TRANSPLANT》 * |
| N POIRIER等: "Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab" antibody", 《AM J TRANSPLANT》 * |
| 李永琴等: "T细胞表面分子CD28及其信号通路的研究", 《贵阳医学院学报》 * |
| 李永琴等: "抗CD28单克隆抗体诱导T细胞活化", 《中国病理生理杂志》 * |
| 葛均波主编: "1.1.2-参与动脉粥样硬化发生的炎症细胞和介质", 《现代心脏病学》 * |
| 邹雄等主编: "第三部分-免疫相关疾病", 《分子免疫学与临床》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| SMT202100185T1 (it) | 2021-05-07 |
| WO2017103003A1 (en) | 2017-06-22 |
| KR20240144440A (ko) | 2024-10-02 |
| LT3390450T (lt) | 2021-06-25 |
| PL3390450T3 (pl) | 2021-09-13 |
| ES2862395T3 (es) | 2021-10-07 |
| US20250051446A1 (en) | 2025-02-13 |
| SI3390450T1 (sl) | 2021-08-31 |
| EP3868785A1 (en) | 2021-08-25 |
| HUE053736T2 (hu) | 2021-07-28 |
| US20180215824A1 (en) | 2018-08-02 |
| HRP20210445T1 (hr) | 2021-06-25 |
| JP6923528B2 (ja) | 2021-08-18 |
| EP3390450B1 (en) | 2021-01-20 |
| US20200115453A1 (en) | 2020-04-16 |
| JP2018538309A (ja) | 2018-12-27 |
| US20220411510A1 (en) | 2022-12-29 |
| KR20180087428A (ko) | 2018-08-01 |
| CY1124141T1 (el) | 2022-05-27 |
| EP3390450A1 (en) | 2018-10-24 |
| RS61958B1 (sr) | 2021-07-30 |
| DK3390450T3 (da) | 2021-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220411510A1 (en) | Anti-CD28 Humanized Antibodies Formulated for Administration to Humans | |
| JP6861301B2 (ja) | 移植片拒絶の予防に使用するための抗cd40抗体 | |
| TW201517917A (zh) | 使用il-17拮抗劑治療類風濕性關節炎之方法 | |
| CN107949571A (zh) | 调控免疫反应的方法及抗体 | |
| CN113271964A (zh) | 化脓性汗腺炎治疗中使用的抗cd40抗体 | |
| KR20170052526A (ko) | 다발성 경화증에 대한 병용 치료 | |
| CN113194996A (zh) | 克拉扎珠单抗用于治疗慢性抗体介导的器官移植物排斥反应 | |
| TW202311293A (zh) | 免疫療法之組合及其用途 | |
| KR20220007086A (ko) | T1dm 및 췌도염의 치료에 사용하기 위한 항-cd40 항체 | |
| HK40058111A (en) | Anti-cd28 humanized antibodies formulated for administration to humans | |
| KR20230154239A (ko) | 항체-매개 이식 거부의 치료에 사용하기 위한 항-cd38 항체 | |
| US20220340687A1 (en) | Methods of treatment using omalizumab | |
| HK1260979A1 (en) | Anti-cd28 humanized antibodies formulated for administration to humans | |
| HK1260979B (en) | Anti-cd28 humanized antibodies formulated for administration to humans | |
| CN119630422A (zh) | 使用白细胞介素-17(il-17)拮抗剂治疗巨细胞动脉炎的方法 | |
| WO2025029859A2 (en) | Treatment of atopic dermatitis | |
| CN116997570A (zh) | 用于治疗抗体介导的移植排斥的抗cd38抗体 | |
| CN116635422A (zh) | 抗cd38抗体及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |